ALZN
Alzamend Neuro, Inc.
There isn't enough reported data to score ALZN yet.
ALZN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ALZN's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
ALZN PE Valuation
ALZN has no meaningful PE right now: it lost money over the past year.
ALZN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect ALZN's losses to shrink, with revenue holding steady.
ALZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2025 | -$27.42 | +$140.88 |
| Q4 2024 | -$59.91 | +$155.19 |
| Q3 2024 | -$95.91 | +$120.09 |
| Q2 2024 | -$138.66 | +$63.84 |
| Q1 2024 | -$168.30 | +$52.33 |
| Q4 2023 | -$215.10 | -$34.97 |
| Q3 2023 | -$216.00 | -$22.37 |
| Q2 2023 | -$202.50 | -$8.87 |
ALZN is still losing money, but far less than before: $2.03 per share over the past year, against $220.63 at its worst in early 2023.
ALZN Quarterly Revenue
ALZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.1M | +$1.2M |
| Q2 2026 | -$2.8M | -$2.1M |
| Q1 2026 | -$1.7M | -$312.7K |
| Q4 2025 | -$1.2M | +$2.2M |
| Q3 2025 | -$2.4M | -$1.3M |
| Q2 2025 | -$688.7K | +$738K |
| Q1 2025 | -$1.4M | +$608K |
| Q4 2024 | -$3.4M | -$1.9M |
ALZN has burned cash in almost every quarter: −$7M over the past year, against −$8M the year before.
ALZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +18% | +674K shares |
| 1 year | +631% | +3.9M shares |
| 3 years | +6049% | +4.4M shares |
ALZN has 4M diluted shares, up 631% from a year ago.
ALZN Net Leverage
ALZN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ALZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.6 | Neutral |
| Stochastic | 24.3 | Neutral |
ALZN's weekly RSI is 45 (neutral) and its Stochastic is 24 (neutral).
ALZN PE vs Healthcare Sector
ALZN has no meaningful PE right now: it lost money over the past year.
ALZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.36 | 4.4% below |
| 20 week MA | $1.42 | 8.5% below |
| 50 week MA | $1.54 | 16% below |
| 100 week MA | $3.36 | 61% below |
| 200 week MA | $145.0 | 99% below |
ALZN is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
ALZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $12,190.5 | $2,902.5 | -76% |
| 2022 | $2,902.5 | $877.3 | -70% |
| 2023 | $877.3 | $80.1 | -91% |
| 2024 | $80.1 | $10.8 | -87% |
| 2025 | $10.8 | $2.02 | -81% |
| 2026 YTD | $2.02 | $1.30 | -36% |
ALZN has finished every year since 2021 lower, and it's down 36% so far in 2026.